Evidence map›Paper›PMID 42086981›Full record

ArticleNature medicine2026

Author Correction: Benralizumab versus placebo for hypereosinophilic syndrome: a randomized, placebo-controlled phase 3 trial.

Princess U Ogbogu, Florence Roufosse, Praveen Akuthota, Piotr Kuna, Matthieu Groh, Andreas Reiter, Akira Yokota, Salman H Siddiqui, Pim G N J Mutsaers, Bing Li and 13 more

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Eosinophilia and the Heart: Evolving Concepts.Current cardiology reports · 2026
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

23 authors.

Princess U OgboguDivision of Pediatric Allergy, Immunology, and Rheumatology, Department of Pediatrics, University Hospitals Rainbow Babies and Children's Hospital, Case Western Reserve University School of Medicine, Cleveland, OH, USA.
Florence RoufosseDepartment of Internal Medicine, Hôpital Universitaire de Bruxelles - Site Erasme, Université Libre de Bruxelles, Brussels, Belgium.
Praveen AkuthotaDivision of Pulmonary, Critical Care, Sleep Medicine and Physiology, Department of Medicine, University of California San Diego, La Jolla, CA, USA.
Piotr KunaDivision of Internal Medicine Asthma and Allergy, Medical University of Lodz, Lodz, Poland.ORCID http://orcid.org/0000-0003-2401-0070
Matthieu GrohUniverstié de Versailles Saint-Quentin-en-Yvelines, Montigny-Le-Bretonneux, France; National Referral Center for Hypereosinophilic Syndromes, Department of Internal Medicine, Clinical Immunology and Hematology, Hôpital Foch, Suresnes, France.
Andreas ReiterDepartment of Hematology and Oncology, University Hospital Mannheim, Heidelberg University, Mannheim, Germany.
Akira YokotaDepartment of Hematology, Chiba Aoba Municipal Hospital, Chiba, Japan.
Salman H SiddiquiNIHR Imperial Biomedical Research Centre, National Heart and Lung Institute, Royal Brompton and Hammersmith Hospitals, Imperial College London, London, UK.
Pim G N J MutsaersDepartment of Hematology, Erasmus University Medical Center, Rotterdam, the Netherlands.
Bing LiState Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China.
Paneez KhouryLaboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Lila M BahadoriRespiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA.
Artur BednarczykRespiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Warsaw, Poland.
Gerben BoumaTranslational Science and Experimental Medicine, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.ORCID http://orcid.org/0000-0002-1465-9178
Laura G BrooksRespiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
Jorge FerreiraRespiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
Hanna GrindebackeRespiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
Calvin N HoRespiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA.ORCID http://orcid.org/0000-0002-3360-9651
Priya JainRespiratory and Immunology, BioPharmaceuticals Medical, AstraZeneca, Cambridge, UK.
Rebecca L PalmerRespiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA.
Maria L JisonRespiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA.
Amy D KlionLaboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA. amy.klion@nih.gov.ORCID http://orcid.org/0000-0002-4986-5326
NATRON study group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID42086981
PMCPMC13278968

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.